Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypo-fractionated Neoadjuvant Radiotherapy for Locally Advanced Gastric Cancer
NCT03427684Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- May 2016
- Primary completion
- Dec 2016
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Chinese Academy of Medical Sciences. Primary endpoints: Maximum Tolerated Dose at 1 month and Dose Limited Toxicity at 1 month. Status: unknown.
Beyond the preview
Go deeper on NCT03427684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03427684.